p53 dysfunction by xeroderma pigmentosum group C defects enhance lung adenocarcinoma metastasis via increased MMP1 expression.

Xeroderma pigmentosum group C (XPC) interacts with hHR23B to recognize DNA damage in global genomic repair. We previously showed that XPC is predominantly affected by its hypermethylation and is associated with an increased occurrence of p53 mutation in lung cancer. Tumors with low XPC mRNA levels had a poorer prognosis than those with high XPC mRNA levels, suggesting that XPC defects may enhance tumor metastasis. However, the underlying mechanism is unclear. Here, we show that p53 transcriptional activity is modulated by XPC, whereby XPC stabilizes hHR23B to form an hHR23B-p53 complex that prevents p53 degradation. In addition, in lung cancer cells and xenograft tumors in nude mice, overexpression of XPC suppresses cell/tumor metastatic ability via repression of matrix metalloproteinase-1 (MMP1) transcription by p53. Among tumors from lung cancer patients, those with low XPC mRNA also tended to have low expression of MMP1 mRNA compared with those with high XPC mRNA. Patients with low XPC mRNA levels also more commonly had tumors with late-stage, distant metastasis (M1), nodal metastasis, and T value (P < 0.001 for tumor stage, distant metastasis, and nodal metastasis; P = 0.006 for t value). In conclusion, p53 dysfunction caused by XPC defects in lung cancers may enhance tumor metastasis via increased MMP1 expression.

[1]  W. Hung,et al.  Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. , 2010, Cancer letters.

[2]  J. Norman,et al.  Mutant p53 Drives Invasion by Promoting Integrin Recycling , 2009, Cell.

[3]  E. Staun-ram,et al.  p53 Mediates epidermal growth factor (EGF) induction of MMP-2 transcription and trophoblast invasion. , 2009, Placenta.

[4]  Ker-Chau Li,et al.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug , 2009, Nature Cell Biology.

[5]  Jan Bergman,et al.  PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. , 2009, Cancer cell.

[6]  S. Benhamou,et al.  Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-deficient/cancer-prone xeroderma pigmentosum group C patients , 2008, Oncogene.

[7]  J. S. Rao,et al.  Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. , 2008, International journal of oncology.

[8]  M. Herlyn,et al.  The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation. , 2007, Genes & development.

[9]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[10]  D. Klimstra,et al.  Loss of p53 and Ink4a/Arf cooperate in a cell autonomous fashion to induce metastasis of hepatocellular carcinoma cells. , 2007, Cancer research.

[11]  Y. Cheng,et al.  Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers , 2007, Oncogene.

[12]  Ya‐Wen Cheng,et al.  Reduced XPC messenger RNA level may predict a poor outcome of patients with nonsmall cell lung cancer , 2007, Cancer.

[13]  K. Wiman,et al.  Reactivation of mutant p53: molecular mechanisms and therapeutic potential , 2007, Oncogene.

[14]  S. Grossman,et al.  hHR23B is required for genotoxic-specific activation of p53 and apoptosis , 2007, Oncogene.

[15]  Dihua Yu,et al.  Wild-type p53 Inhibits Nuclear Factor-κB–Induced Matrix Metalloproteinase-9 Promoter Activation: Implications for Soft Tissue Sarcoma Growth and Metastasis , 2006, Molecular Cancer Research.

[16]  A. Fornace,et al.  Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  I. Stamenkovic,et al.  Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. , 2005, Cancer research.

[18]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[19]  Y. Maehara,et al.  The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer. , 2004, Lung cancer.

[20]  S. Grossman,et al.  A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway , 2004, Oncogene.

[21]  G. Firestein,et al.  p53 down‐regulates matrix metalloproteinase‐1 by targeting the communications between AP‐1 and the basal transcription complex , 2004, Journal of cellular biochemistry.

[22]  Su Jeong Song,et al.  The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC–Cdc20 complex , 2004, Nature Cell Biology.

[23]  A. Hengstermann,et al.  Involvement of the DNA Repair Protein hHR23 inp53Degradation , 2003, Molecular and Cellular Biology.

[24]  Hongbing Shen,et al.  Smoking, DNA repair capacity and risk of nonsmall cell lung cancer , 2003, International journal of cancer.

[25]  J. Hoeijmakers,et al.  A novel regulation mechanism of DNA repair by damage-induced and RAD23-dependent stabilization of xeroderma pigmentosum group C protein. , 2003, Genes & development.

[26]  R. Visse,et al.  Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases: Structure, Function, and Biochemistry , 2003, Circulation research.

[27]  Galina Selivanova,et al.  Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. , 2002, Carcinogenesis.

[28]  S. Velasco-Miguel,et al.  A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions , 2002, Oncogene.

[29]  Constance E. Brinckerhoff,et al.  Matrix metalloproteinases: a tail of a frog that became a prince , 2002, Nature Reviews Molecular Cell Biology.

[30]  Galina Selivanova,et al.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound , 2002, Nature Medicine.

[31]  Hiroshi Sato,et al.  Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. , 2002, Lung cancer.

[32]  M. J. Moné,et al.  Sequential assembly of the nucleotide excision repair factors in vivo. , 2001, Molecular cell.

[33]  H. McLeod,et al.  Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. , 2001, Oncology reports.

[34]  K. Mimori,et al.  Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. , 2000, Oncology reports.

[35]  K. H. Huang,et al.  DNA adduct level in lung tissue may act as a risk biomarker of lung cancer. , 2000, European journal of cancer.

[36]  T. Inoue,et al.  Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. , 1999, International journal of molecular medicine.

[37]  I. Sekine,et al.  Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[38]  J. Keski‐Oja,et al.  Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas , 1999, British Journal of Cancer.

[39]  P. Davaris,et al.  Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. , 1999, Human pathology.

[40]  D K Burns,et al.  Mutational inactivation of the xeroderma pigmentosum group C gene confers predisposition to 2-acetylaminofluorene-induced liver and lung cancer and to spontaneous testicular cancer in Trp53-/- mice. , 1999, Cancer research.

[41]  C. N. Rao,et al.  Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. , 1999, Biochemical and biophysical research communications.

[42]  P. J. van der Spek,et al.  Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. , 1998, Molecular cell.

[43]  J. McKay,et al.  Matrix metalloproteinase‐1 is associated with poor prognosis in oesophageal cancer , 1998, The Journal of pathology.

[44]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[45]  John E. Fothergill,et al.  Matrix metalloproteinase–1 is associated with poor prognosis in colorectal cancer , 1996, Nature Medicine.

[46]  A. Bradley,et al.  High susceptibility to ultraviolet-induced carcinogenesis in mice lacking XPC , 1995, Nature.

[47]  M. Tonato,et al.  Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. , 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[48]  B. Fiedler,et al.  Interference of antihypertrophic molecules and signaling pathways with the Ca2+-calcineurin-NFAT cascade in cardiac myocytes. , 2004, Cardiovascular research.

[49]  Chinfei Chen,et al.  Gender difference in DNA adduct levels among nonsmoking lung cancer patients , 2001, Environmental and molecular mutagenesis.